TLDR
- Vertex shares gained approximately 5-7% following povetacicept’s success in achieving its primary endpoint in a phase 3 trial for IgA nephropathy.
- The treatment reduced urine protein levels by 52% at the 36-week mark, compared to 4.3% among placebo recipients.
- The drug decreased a damaging antibody by 79.3% while eliminating blood in urine for more than 85% of trial participants.
- Vertex expects to submit for FDA accelerated approval before the end of March, utilizing a priority review voucher to shorten review duration to six months.
- Wall Street analysts from Cantor and Evercore upgraded their projections, establishing price targets at $590 and $530 respectively.
Vertex Pharmaceuticals shares advanced following the announcement that povetacicept, its investigational kidney treatment, delivered robust results in a phase 3 clinical trial. The stock climbed as high as 7% during after-hours trading Monday, maintaining gains around 5% during premarket hours Tuesday.
Vertex Pharmaceuticals Incorporated, VRTX
The therapy targets IgA nephropathy, an autoimmune condition that damages kidney tissue. A significant percentage of patients face kidney failure within two decades of receiving their diagnosis when left untreated.
Trial participants receiving povetacicept demonstrated a 52% decrease in urine protein following 36 weeks of treatment. Those receiving placebo experienced merely a 4.3% reduction. Elevated urine protein serves as a critical indicator of kidney deterioration.
The treatment additionally lowered levels of a destructive antibody by 79.3%. More than 85% of participants experienced clearance of blood from their urine, outperforming the placebo group. According to Vertex, the drug, administered via injection once monthly, demonstrated a favorable safety profile with good tolerability.
The interim results encompassed 199 participants who had reached the 36-week treatment milestone. The complete study enrolls 605 patients and extends over two years, evaluating whether the therapy prevents long-term decline in kidney function.
Vertex announced its intention to file a complete FDA application before March ends. The company will leverage a priority review voucher, reducing the typical review period from 10 months to six.
Wall Street Reacts
Wall Street analysts responded swiftly to the announcement. Evercore ISI’s Cory Kasimov described the findings as a “pretty good validation” of Vertex’s $4.9 billion Alpine Immune Sciences acquisition in 2024, the source of povetacicept. His rating remains Outperform with a $530 price target.
Cantor’s Carter Gould characterized the results as “the first major step in unlocking the renal franchise,” projecting potential peak sales exceeding $10 billion. Gould maintains an Overweight rating on Vertex with a $590 price target.
BMO Capital Markets analyst Evan Seigerman stated the data “firmly places povetacicept as a clear competitor and potential leader” within the IgA nephropathy treatment landscape.
How It Stacks Up Against Rivals
According to Seigerman, the results demonstrate advantages when compared to Otsuka’s approved therapy Voyxact and Vera Therapeutics’ investigational compound atacicept.
Vertex has built its reputation primarily through its cystic fibrosis portfolio, which contributed to the company’s market capitalization exceeding $100 billion. The IgA nephropathy program represents a strategic expansion into kidney disease treatment.
Shares traded at $485.10 during premarket hours Tuesday. The complete two-year trial results remain forthcoming.
